FRAZER, Pa., Nov. 1 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq:
CEPH) announced today that Valli F. Baldassano, Esq., has been appointed to
the new position of Executive Vice President and Chief Compliance Officer.
In this role, Ms. Baldassano reports directly to Chairman and CEO, Frank
Baldino Jr., Ph.D., with dotted line reporting to the audit committee of
the board of directors.
(Photo: http://www.newscom.com/cgi-bin/prnh/20071101/NETH162 )
"Valli brings a unique perspective on compliance issues as she has
represented both corporations in the pharmaceutical industry and the U.S.
government," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "We are
pleased to have her guide us through this increasingly challenging
regulatory environment. Moreover, our decision to make the chief compliance
officer position an executive officer of the company underscores the
importance of compliance in our organization."
Ms. Baldassano has 21 years experience of legal experience with a
strong background in healthcare fraud and compliance issues. Most recently
she served as a Partner with Fox Rothschild LLP in Philadelphia where she
was a member of the Litigation Department. Her corporate law experience
includes eight years in the pharmaceutical industry in senior level
compliance positions at Schering-Plough and the former Pharmacia. While at
Schering, she negotiated and managed the implementation of two corporate
integrity agreements with the Department of Health and Human Services,
Office of Inspector General.
Previously, Ms. Baldassano was an Assistant United States Attorney in
the Criminal Division of the United States Attorney's Office for the
Eastern District of Pennsylvania, where she investigated and tried federal
criminal cases involving healthcare fraud and public corruption.
Ms. Baldassano received her Juris Doctor degree from Syracuse
University and holds a Bachelor of Arts from Georgetown University.
Cephalon, Inc.
Cephalon, Inc. is an international biopharmaceutical company, recently
inducted into the World Economic Forum Community of Global Growth
Companies. For 20 years, the company has been dedicated to the discovery,
development and commercialization of innovative products in four core
therapeutic areas: central nervous system, pain, oncology and addiction. A
member of the Fortune 1000, Cephalon currently employs approximately 3,000
people in the United States and Europe. U.S. sites include the company's
headquarters in Frazer, Pennsylvania, and offices, laboratories or
manufacturing facilities in West Chester, Pennsylvania, Salt Lake City,
Utah, and suburban Minneapolis, Minnesota. Cephalon's European headquarters
are located in Maisons-Alfort, France.
The company's proprietary products in the United States include:
AMRIX(TM) (cyclobenzaprine hydrochloride extended-release capsules),
PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet)
[C-II], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone
for extended-release injectable suspension), GABITRIL(R) (tiagabine
hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral
transmucosal fentanyl citrate) [C-II]. The company also markets numerous
products internationally. Full prescribing information on its U.S. products
is available at http://www.cephalon.com or by calling 1-800-896-5855.
In addition to historical facts or statements of current condition,
this press release may contain forward-looking statements. Forward-looking
statements provide Cephalon's current expectations or forecasts of future
events. These may include statements regarding anticipated scientific
progress on its research programs, development of potential pharmaceutical
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects for
its products, sales and earnings guidance, and other statements regarding
matters that are not historical facts. You may identify some of these
forward-looking statements by the use of words in the statements such as
"anticipate," "estimate," "expect," "project," "intend," "plan," "believe"
or other words and terms of similar meaning. Cephalon's performance and
financial results could differ materially from those reflected in these
forward-looking statements due to general financial, economic, regulatory
and political conditions affecting the biotechnology and pharmaceutical
industries as well as more specific risks and uncertainties facing Cephalon
such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed
with the U.S. Securities and Exchange Commission. Given these risks and
uncertainties, any or all of these forward-looking statements may prove to
be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Furthermore, Cephalon does not intend to update
publicly any forward-looking statement, except as required by law. The
Private Securities Litigation Reform Act of 1995 permits this discussion.
SOURCE Cephalon, Inc.
 back to top
Related links:
http://www.cephalon.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20071101/NETH162
http://www.prnewswire.com/comp/134563.html /
CONTACT:
Media, Sheryl Williams, +1-610-738-6493,
swilliam@cephalon.com, or Investors, Robert (Chip) Merritt,
+1-610-738-6376, cmerritt@cephalon.com, both of Cephalon
|
